Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Alpha and Omega of Lifestyle Therapy (Alpha&Omega)

8. August 2022 aktualisiert von: Inland Norway University of Applied Sciences

Alpha and Omega of Lifestyle Therapy - Resistance Training and Ingestion of n-3 Polyunsaturated Fatty Acids to Improve Health and Muscle Functions in Individuals With Obesity and Healthy Controls

The study aims to investigate the effects of double-blinded, randomized placebo-controlled n3-fatty acid supplementation (1000 mg day-1) and 13 weeks of resistance training on muscle function/biology and systemic health in individuals with obesity (BMI>30) and lean individuals (BMI<30)

Studienübersicht

Detaillierte Beschreibung

Lifestyle therapy is important for treating lifestyle-related morbidities such as obesity. Such therapy often includes exercise and nutrition, and leads to improved health, functionality and quality of life. Unfortunately, obesity leads to adverse changes in the physiological milieu, including inflammation and altered nutritional status such as reduced omega-3:omega-6 ratios. Indeed, inadequate omega 3 levels are common even among lean individuals. This may negatively affect the outcome of lifestyle therapy with exercise, particularly those involving resistance training, contributing to the large heterogeneity seen in training responses. In accordance with this, many individuals (including both lean and obese subjects) fail to improve muscle biology/functions and health, including failure to increase muscle mass and strength, failure to improve glucose handling and inflammatory status. This makes general lifestyle therapy recommendations ineffective. Here, we investigate effects of double-blinded, randomized placebo-controlled n3-fatty acid supplementation (1000 mg day-1) and 13 weeks of low- and high-load resistance training on muscle growth/function/biology and health in individuals with obesity (BMI>30, n=60) and lean controls (BMI<30, n=60). Each participant will perform two different training protocols, one on each leg. The supplement period will commence 7 weeks prior to the onset of the strength training intervention to ensure adequate omega-3 biology at the onset of training. Analyses include assessment of the separate and combined effects of n3-supplementation and obesity on training responses to resistance training, measured as muscle mass, muscle strength/functionality, muscle biological traits, and systemic health variables such as hormone/inflammation/glucose biology, adipose tissue biology/mass, gut microbiome and health-related quality of life. The project will provide important insight into the feasibility of resistance training and n-3 fatty acid supplementation for treating individuals with obesity, paving the way for personalized lifestyle therapy.

The study has two defined main outcome measures, targeting the combined effects of omega-3 and strength training on i) muscle thickness of the thigh (measured using ultrasound; this main outcome measure targets the effects of the intervention on muscle growth), and ii) glucose tolerance (measured using an oral glucose test; this main outcome measure targets the effects of the intervention on improvements in health).

In our analytical approach, we will use a mixed model-approach to assess the main effects of the intervention, mainly defined as changes from before to after the resistance training intervention. Importantly, for health variables such as glucose tolerance, analyses will be performed by accounting for individual variation at baseline, as any beneficial effect can be expected to be higher/present only in individuals with a pathological/diseased starting point. Notably, for many variables, we will collect data from two additional time points (pre-supplementation and after two weeks of familiarization to training). These data will provide insight into additional perspectives, such as the effects of omega-3 intake-only on glucose tolerance, which will bring additional depth to our conclusions (these analyses are not necessarily specified in the Outcome Measures section). For other data, such as primary cultivation of skeletal muscle and muscle mitochondrial respiration, data will only be collected from a randomized subset of participants. For analyses of the effects of the intervention on obesity-related pathophysiologies and health-related quality of life, data from a group of non-intervention individuals will act as reference values (data sampled alongside the intervention). Finally, we will use regression analyses to explain individual differences in training responses, with particular emphasis on muscle hypertrophy/glucose tolerance and their mechanistic origin of nature.

2021/08: The number of anticipated participants was increased from 120 to 150 due to circumstances relating to the SARS-CoV-2 pandemic

Studientyp

Interventionell

Einschreibung (Voraussichtlich)

150

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Lillehammer, Norwegen
        • Inland Norway University of Applied Sciences

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

30 Jahre bis 60 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Untrained (less than 2 sessions of resistance exercise per month and less than 3 hours of endurance exercise per week)

Exclusion Criteria:

  • Unstable cardiovascular disease
  • Injuries affecting the ability to perform heavy resistance exercise
  • Mental illness
  • Allergy to local anesthesia
  • Smoking
  • Use of medicine or drugs containing steroids the last two months prior to inclusion

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Grundlegende Wissenschaft
  • Zuteilung: Zufällig
  • Interventionsmodell: Fakultätszuweisung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Kein Eingriff: Kontrolle
Kein Eingriff
Experimental: Omega 3

Intake of 1 gram omega-3 (capsules) per day for 20 weeks

+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)

High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)
1 gram of omega-3 per day for 20 weeks
Andere Namen:
  • N-3 PUFA
Placebo-Komparator: Placebo

Intake of 1 gram sunflower oleic oil (capsules) per day for 20 weeks

+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)

High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)
1 gram of sunflower oleic oil per day for 20 weeks

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Muscle thickness, ultrasound
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Muscle thickness of vastus lateralis and vastus intermedius measured using ultrasound
Changes from before to after the resistance training intervention (week 8 to 20)
Glucose tolerance
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Glucose tolerance measured using an oral glucose tolerance test
Changes from before to after the resistance training intervention (week 8 to 20)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Lean body mass
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Lean body mass measured using whole-body DXA scan
Changes from before to after the resistance training intervention (week 8 to 20)
Fat mass
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Fat mass measured using whole-body DXA scan
Changes from before to after the resistance training intervention (week 8 to 20)
Visceral fat mass
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Visceral fat mass measured using whole-body DXA scan
Changes from before to after the resistance training intervention (week 8 to 20)
Muscle mass, MRI
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Thigh muscle cross sectional area/volume measured using magnetic resonance imaging (MRI)
Changes from before to after the resistance training intervention (week 8 to 20)
Muscle mass, immunohistochemistry
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Fibre type-specific muscle-fibre cross-sectional area measured using immunohistochemistry
Changes from before to after the resistance training intervention (week 8 to 20)
Muscle mass, combined measure
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Muscle mass of the legs measured as the weighted average of data from ultrasound, MRI, immunohistochemistry and DXA measurements
Changes from before to after the resistance training intervention (week 8 to 20)
Muscle fibre type composition
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Muscle fibre type composition measured using immunohistochemistry
Changes from before to after the resistance training intervention (week 8 to 20)
Myonuclear number
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Fiber type-specific myonuclear number measured using immunohistochemistry
Changes from before to after the resistance training intervention (week 8 to 20)
Muscle satellite cell number
Zeitfenster: Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
Fiber type-specific muscle satellite cell number measured using immunohistochemistry
Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
Muscle capillarization
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Fiber type-specific muscle capillarization measured using immunohistochemistry
Changes from before to after the resistance training intervention (week 8 to 20)
Fat infiltration (muscle)
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Fat infiltration in thigh muscle measured using magnetic resonance imaging (MRI)
Changes from before to after the resistance training intervention (week 8 to 20)
Muscle quality
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Muscle strength measured per muscle mass of the legs
Changes from before to after the resistance training intervention (week 8 to 20)
Unilateral lower body maximal strength
Zeitfenster: Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
The ability of muscles of the lower body to exert maximal force during dynamic movements
Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
Unilateral lower body isokinetic muscle strength
Zeitfenster: Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
The ability of the knee extensors to exert maximal force during isokinetic movements
Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
Unilateral lower body isometric muscle strength
Zeitfenster: Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
The ability of the knee extensors to exert maximal force during isometric actions
Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
Peak power output during one-legged cycling
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Maximal cycling performance measured as peak power output (Watt) during an incremental one-legged cycling test
Changes from before to after the resistance training intervention (week 8 to 20)
Oxygen consumption during one-legged cycling
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
The ability to consume oxygen during an incremental one-legged cycling test
Changes from before to after the resistance training intervention (week 8 to 20)
Unilateral lower body muscle endurance
Zeitfenster: Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
The ability of muscles of the lower body to perform repeated dynamic contractions at a specified submaximal load (70% of 1RM) to exhaustion
Changes throughout the course of the resistance training intervention (weeks 8, 10 and 20)
Waist circumference
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Circumference of the waist measured using measuring tape
Changes from before to after the resistance training intervention (week 8 to 20)
Blood pressure at rest
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Blood pressure at rest measured using an automated upper-arm blood pressure cuff
Changes from before to after the resistance training intervention (week 8 to 20)
Hemoglobin glycosylation (HbA1c)
Zeitfenster: Changes throughout the course of the intervention (weeks 0, 8 and 20)
Long-term glucose levels measured as hemoglobin glycosylation of the metabolic syndrome such as waist circumference, blood pressure at rest, lipid profile ( hemoglobin glycosylation (HbA1c) and fasting blood glucose
Changes throughout the course of the intervention (weeks 0, 8 and 20)
Fasting blood glucose
Zeitfenster: Changes throughout the course of the intervention (weeks 0, 8 and 20)
Fasting blood glucose measured in serum
Changes throughout the course of the intervention (weeks 0, 8 and 20)
N-3 PUFA (blood)
Zeitfenster: Changes throughout the course of the intervention (weeks 0, 8 and 20)
Omega-3 (DHA/EPA) levels in blood
Changes throughout the course of the intervention (weeks 0, 8 and 20)
Inflammatory characteristics of peripheral blood mononuclear cell (PBMC)
Zeitfenster: Throughout the course of the intervention (weeks 0, 8 and 20)
Expression of genes associated with inflammation and lipid metabolism in peripheral blood mononuclear cell measured using quantitative PCR
Throughout the course of the intervention (weeks 0, 8 and 20)
Lipid concentrations in blood
Zeitfenster: Changes throughout the course of the intervention (weeks 0, 8 and 20)
Concentrations of various lipids and lipid metabolites such as triglycerides, LDL, HDL, ceramides, dihydroceramides, glucosylceramides, and lactosylceramides measured in serum using tageted metabolomics
Changes throughout the course of the intervention (weeks 0, 8 and 20)
Nutritent concentrations in blood
Zeitfenster: Changes throughout the course of the intervention (weeks 0, 8 and 20)
Concentrations of nutrients (such as amino acids) and ions (such as iron and calcium) measured in serum
Changes throughout the course of the intervention (weeks 0, 8 and 20)
Hormone concentrations in blood
Zeitfenster: Changes throughout the course of the intervention (weeks 0, 8 and 20)
Concentrations of hormones such as testosterone, growth hormone, thyroid hormones, cortisol and insulin (as well as c-peptide) measured in serum
Changes throughout the course of the intervention (weeks 0, 8 and 20)
Concentrations of inflammatory factors in blood
Zeitfenster: Changes throughout the course of the intervention (weeks 0, 8 and 20)
Levels of inflammatory factors such as IL6, CRP and NFkB in serum
Changes throughout the course of the intervention (weeks 0, 8 and 20)
Muscle fractional synthesis rate
Zeitfenster: Week 18 to 20
Protein/RNA synthesis rate measured using heavy water (deuterium) and chromatography/spectrometry
Week 18 to 20
Gene expression in skeletal muscle (intervention)
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
RNA (e.g. messenger RNA, ribosomal RNA, microRNA, long non-coding RNA) abundances in m. vastus lateralis, measured both as targeted genes and at the level of the transcriptome
Changes from before to after the resistance training intervention (week 8 to 20)
Gene expression in skeletal muscle (familiarization)
Zeitfenster: Changes from before to after familiarization to resistance exercise (week 8 to 10)
RNA (e.g. messenger RNA, ribosomal RNA, microRNA, long non-coding RNA) abundances in m. vastus lateralis, measured both as single genes and at the level of the transcriptome
Changes from before to after familiarization to resistance exercise (week 8 to 10)
Protein abundance in skeletal muscle (intervention)
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Levels of proteins and their modification status (e.g. phosphorylation) in m. vastus lateralis, measured at the level of single proteins and at the level of the proteome
Changes from before to after the resistance training intervention (week 8 to 20)
Protein abundance in skeletal muscle (familiarization)
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 10)
Levels of proteins and their modification status (e.g. phosphorylation) in m. vastus lateralis, measured at the level of single proteins and at the level of the proteome
Changes from before to after the resistance training intervention (week 8 to 10)
Mitochondrial functions in muscle
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
The ability of muscle mitochondria (extracted from muscle homogenate) to synthesize ATP in vitro
Changes from before to after the resistance training intervention (week 8 to 20)
Gene expression in subcutaneous fat
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
RNA (e.g. messenger RNA, ribosomal RNA, microRNA, long non-coding RNA) abundances in subcutaneous fat, measured as targeted genes
Changes from before to after the resistance training intervention (week 8 to 20)
Satellite cell proliferation and myotube growth (in vitro)
Zeitfenster: Changes from before to after N3-supplementation-only (week 0 to 8)
The ability of muscle satellite cells (extracted from muscle homogenate) to proliferate (rates of cell division), differentiate into myotubes and subsequently grow (rates of change in myotube size) in primary cultures
Changes from before to after N3-supplementation-only (week 0 to 8)
Musculoskeletal pain (Nordic Pain Questionnaire)
Zeitfenster: Changes throughout the course of the training intervention (weeks 0, 8 and 20)
Musculoskeletal pain measured using The standardized Nordic Pain Questionnaire
Changes throughout the course of the training intervention (weeks 0, 8 and 20)
Musculoskeletal pain (VAS)
Zeitfenster: Changes throughout the course of the training intervention (weeks 0, 8 and 20)
Musculoskeletal pain measured using VAS-scale (1-10)
Changes throughout the course of the training intervention (weeks 0, 8 and 20)
Gastrointestinal symptoms
Zeitfenster: Changes throughout the course of the training intervention (weeks 0, 8 and 20)
Gastrointestinal symptoms such as abdominal discomfort and pain, measured using Rome IV criteria
Changes throughout the course of the training intervention (weeks 0, 8 and 20)
Gut microbiome (feces, N3-supplementation-only)
Zeitfenster: Changes from before to after N3-supplementation-only (week 0 to 8)
Relative composition of the gut microbiome measured using quantitative polymerase chain reaction
Changes from before to after N3-supplementation-only (week 0 to 8)
Gut microbiome (feces, training intervention)
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Relative composition of the gut microbiome measured using quantitative polymerase chain reaction
Changes from before to after the resistance training intervention (week 8 to 20)
Fecal short-chained fatty acids (N3-supplementation-only)
Zeitfenster: Changes from before to after N3-supplementation-only (week 0 to 8)
Short chained fatty acids measured in feces
Changes from before to after N3-supplementation-only (week 0 to 8)
Fecal short-chained fatty acids (training intervention)
Zeitfenster: Changes from before to after the resistance training intervention (week 8 to 20)
Short chained fatty acids measured in feces
Changes from before to after the resistance training intervention (week 8 to 20)
Arterial stiffness
Zeitfenster: Throughout the course of the intervention (week 0, 8 and 20)
Arterial stiffness measured using pulse-wave velocity
Throughout the course of the intervention (week 0, 8 and 20)
Health-related quality of life (SF-36)
Zeitfenster: Changes throughout the course of the intervention (week 0, 8 and 20)
Health-related quality of life measured using the SF-36 questionnaire
Changes throughout the course of the intervention (week 0, 8 and 20)
Health-related quality of life in overweight/obesity
Zeitfenster: Changes throughout the course of the intervention (week 0, 8 and 20)
Health-related quality of life in overweight/obesity individuals measured using The impact of weight on quality of life (IWQOL) questionnaire
Changes throughout the course of the intervention (week 0, 8 and 20)
Health-related quality of life (PANAS)
Zeitfenster: Changes throughout the course of the intervention (week 0, 8 and 20)
Health-related quality of life measured using the Positive and Negative Affect Schedule (PANAS) questionnaire
Changes throughout the course of the intervention (week 0, 8 and 20)
Activities of daily living
Zeitfenster: Changes throughout the course of the intervention (week 0, 8 and 20)
Activities of daily living (e.g. time spent in physical activity, intensities of activities) measured using questionnaire
Changes throughout the course of the intervention (week 0, 8 and 20)

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Training diary relating to the intervention protocol
Zeitfenster: Weeks 8 to 20
Information about intervention-specific training, including training frequency, volume and load
Weeks 8 to 20
Dietary registration
Zeitfenster: Week 0, 8 and 20
Dietary registration measured using a food frequency questionnaire, assessing nutritional composition, energy intake and habitual patterns of dietary intake
Week 0, 8 and 20

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Stian Ellefsen, PhD, Inland Norway University of Applied Sciences

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

2. September 2019

Primärer Abschluss (Tatsächlich)

30. März 2022

Studienabschluss (Voraussichtlich)

1. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

19. Januar 2020

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

19. Februar 2020

Zuerst gepostet (Tatsächlich)

21. Februar 2020

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

9. August 2022

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

8. August 2022

Zuletzt verifiziert

1. August 2022

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • Trainome 2019#015

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren